Navigation Links
Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
Date:2/20/2008

torical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of February 20, 2008 and the Company does not intend to update this information.

OSTEOTECH, INC. and Subsidiaries

CONSOLIDATED STATEMENTS OF OPERATIONS

(dollars in thousands, except per share data)

Three Months Year Ended

Ended December 31, December 31,

2006

2007 (restated) 2007 2006

Revenue $ 26,939 $ 25,431 $104,277 $ 99,241

Cost of revenue 12,532 13,322 50,555 51,439

Gross profit
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
4. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
7. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
10. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... State University have developed a technique for controlling the ... voltages, opening the door to a new generation of ... hinges on the fact that the oxide "skin" of ... acts as a surfactant, lowering the surface tension ... researchers used a liquid metal alloy of gallium and ...
(Date:9/15/2014)... MORRISVILLE, NC (PRWEB) September 15, 2014 ... newly developed deep imaging OCT system for the optical ... , The EnvisuTM S4410 SDOCT for Contact ... measurements for standard and high complexity contact lens, IOL ... allows imaging of a complete contact lens immersed in ...
(Date:9/15/2014)... The chemistry, taste, and health effects of tea can vary ... the nonprofit American Botanical Council (ABC). Recent research by ... on the phytochemical compounds in tea ( Camellia sinensis ) ... in the Yunnan province of southwestern ... future of medicinal botanicals. Dr. Ahmed,s report on ...
(Date:9/15/2014)... septiembre de 2014 La segunda anual International ... 12 al 18 de octubre. Como iniciativa conjunta de la ... compañías miembro s, la IPAW se ha diseñado para: ... a la colección de fuentes de plasma , Reconocimiento ... y mejorar las vidas , Aumento del conocimiento sobre ...
Breaking Biology Technology:Researchers control surface tension to manipulate liquid metals 2Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3
... Ondine Biopharma,Corporation (the "Company" or "Ondine", TSX: ... photodisinfection based products, today,announced its financial results ... 2008., "During the past quarter we ... photodisinfection technology and we are leveraging our,successes ...
... 14 Palatin Technologies,Inc. (Amex: PTN ) ... clinical,trial of PL-3994, a novel, long-acting natriuretic peptide ... heart failure (HF). The,Phase 2a trial was a ... volunteers with controlled hypertension who,received the medication or ...
... professor of aerospace and ocean engineering at Virginia Tech, ... E. Powe Junior Faculty Award. The award will support ... are new material and structural systems that have the ... "I believe these innovative materials will lead to new ...
Cached Biology Technology:Ondine Biopharma Announces Second Quarter 2008 Financial Results 2Ondine Biopharma Announces Second Quarter 2008 Financial Results 3Ondine Biopharma Announces Second Quarter 2008 Financial Results 4Ondine Biopharma Announces Second Quarter 2008 Financial Results 5Ondine Biopharma Announces Second Quarter 2008 Financial Results 6Ondine Biopharma Announces Second Quarter 2008 Financial Results 7Ondine Biopharma Announces Second Quarter 2008 Financial Results 8Ondine Biopharma Announces Second Quarter 2008 Financial Results 9Ondine Biopharma Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 11Ondine Biopharma Announces Second Quarter 2008 Financial Results 12Ondine Biopharma Announces Second Quarter 2008 Financial Results 13Ondine Biopharma Announces Second Quarter 2008 Financial Results 14Ondine Biopharma Announces Second Quarter 2008 Financial Results 15Ondine Biopharma Announces Second Quarter 2008 Financial Results 16Ondine Biopharma Announces Second Quarter 2008 Financial Results 17Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure 3
(Date:9/15/2014)... PULLMAN, Wash.Washington State University researchers have found "the most ... that can be used to transfer valuable genes ... the way for breeders to develop wheat varieties with ... a legion of genetic tools that can reduce crop ... hurdles and controversy of Genetically Modified Organisms, or GMOs., ...
(Date:9/15/2014)... understand how the fish communities might shift under ... of environmental data to inform future decisions relating ... said Paula Whitfield, a research ecologist at NOAA,s ... lead author of the study. , The North ... where historically, both temperate and tropical species live, ...
(Date:9/15/2014)... the Department of Science and Technology in Society in ... Virginia Tech, has won a 2014 National Science Foundation ... and problems of creating a global nuclear emergency response ... Nuclear Power Plant in March 2011 was a turning ... Schmid said. Three of the plant,s six nuclear reactors ...
Breaking Biology News(10 mins):WSU researchers find 'most famous wheat gene' 2Study finds warming Atlantic temperatures could increase range of invasive species 2'Nuclear disasters don't respect national boundaries' 2
... German . Scientists at the Max Planck ... insights for stem cell research which are also applicable to ... treatments. As Rolf Kemler,s research group discovered, a molecular link ... telomeres and a signalling pathway known as the Wnt/β-signalling pathway. ...
... smaller than the nano as it is the equivalent of ... green algae of this imperceptible size existing in the Bilbao ... estuary. This has enabled him to identify six genera and ... been catalogued in these waters. He has also put forward ...
... toward treating disease with minute capsules containing not drugs ... making the drug. In an article in ACS, journal ... nano-sized capsules that contain the genetically coded instructions, plus ... that can be switched on with an external signal. ...
Cached Biology News:A nanoscopic look at the estuary's green algae 2A nanoscopic look at the estuary's green algae 3
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
... value of your microarray data using ... support you need from consultation to ... up to date methods. Utilize our ... Expression Profiling Service or from your ...
... Maximize the value of your microarray ... the support you need from consultation to ... to date methods. Utilize our expertise in ... or from your own microarray experiments., ,Normalization ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: